561. Reduction of RSV-associated hospitalization rates during the 2024-2025 RSV Season among infants <6 months of age

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Ayzsa F. Tannis, Leah A. Goldstein, Geoffrey A. Weinberg, Mary Allen Staat, Daniel C. Payne, Natasha Halasa, Leila C. Sahni, Julie A. Boom, Peter G Szilagyi, Janet A. Englund, Eileen J. Klein, Ariana P. Toepfer
+9 more Abigail Salthouse, Casey M Kalman, Laura S Stewart, John Williams, Marian G. Michaels, Jennifer E. Schuster, Rangaraj Selvarangan, Fatimah S. Dawood, Heidi L. Moline
DOI: 10.1093/ofid/ofaf695.170
Cited by: 0

Abstract

Abstract Background Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants. The 2024-2025 season was the first full season with widely available RSV prevention products, (nirsevimab and maternal RSV vaccination) recommended for all infants aged < 8 months. To assess the impact of these products on RSV-associated hospitalizations, we compared RSV-associated hospitalization rates in infants aged < 6 months from 2017-2020 to 2024-2025.Table 1.Incidence rates of RSV-associated hospitalizations per 1,000 infants by site among infants

Fields of Study & Subjects

Respiratory viral infections research Pediatric health and respiratory diseases SARS-CoV-2 and COVID-19 Research

Publication details

Journal / source
Open Forum Infectious Diseases
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN